Somatostatinoma: Clinical Trials

33 trials for Somatostatinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 7 terminated, 3 active not recruiting, 3 withdrawn. 33 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 233Completed 20, Terminated 7, Active not recruiting 3, Withdrawn 3
Phase 32Completed 1, Terminated 1

Follow Somatostatinoma: new trials by email Literature Review of Somatostatinoma trials Research Report on Somatostatinoma

Trials (filtered) newest first · largest first

All 33 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma
Phase 2Active not recruitingUniversity of Michigan Rogel Cancer Center172024-04-192026-05-14
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Fluorouracil, Leucovorin, Liposomal Irinotecan - Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma
Phase 2TerminatedRoswell Park Cancer Institute112019-06-172025-01-30
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Sapanisertib - Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Phase 2CompletedNational Cancer Institute (NCI)132017-04-282023-10-17
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)7982017-01-302026-06-17
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma
Phase 2CompletedUniversity of Southern California32016-08-162021-12-15
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Capecitabine, Carboplatin, Cisplatin - Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Phase 2Active not recruitingECOG-ACRIN Cancer Research Group672015-11-062026-11-02
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Palbociclib - Pancreatic Neuroendocrine Cancer
Phase 2CompletedGrupo Espanol de Tumores Neuroendocrinos212015-05-012018-01-23
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate - Pancreatic Neuroendocrine Carcinoma
Phase 2CompletedGustave Roussy, Cancer Campus, Grand Paris842015-02-012025-04-20
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma
Phase 2TerminatedEmory University22014-11-012017-02-03
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma
Phase 2WithdrawnAcademic and Community Cancer Research United2014-10-012017-07-19
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)222014-06-182020-03-23
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
everolimus, placebo - Gastrinoma, Glucagonoma
Phase 2TerminatedECOG-ACRIN Cancer Research Group22014-04-102023-06-29
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
temozolomide, capecitabine - Gastrinoma, Glucagonoma
Phase 2CompletedECOG-ACRIN Cancer Research Group1442013-08-082026-09-29
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide - Adult Medulloblastoma, Childhood Medulloblastoma
Phase 2CompletedSue O'Dorisio682013-04-012021-09-22
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma
Phase 2CompletedShaheen Shagufta202012-12-012024-02-06
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Bortezomib, Panobinostat - Pancreatic Cancer
Phase 2TerminatedMasonic Cancer Center, University of Minnesota72010-09-012017-12-28
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)2522009-09-082019-01-25
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Phase 2CompletedEastern Cooperative Oncology Group462008-11-072023-07-05
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Phase 2CompletedNational Cancer Institute (NCI)522007-03-012020-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Indium-111 pentetreotide - Neuroendocrine Tumors
Phase 2 / Phase 3CompletedRadio Isotope Therapy of America2002005-08-012023-04-03

Showing 20 of 33. Sign in to see all of them.

Narrower conditions

Glucagonoma (20)  ·  Insulinoma (20)  ·  Carcinoma, Islet Cell (18)  ·  Gastrinoma (18)  ·  Vipoma (10)  ·  Adenoma, Islet Cell (9)  ·  Neoplasms (6)  ·  Neuroendocrine Tumors (6)  ·  Pheochromocytoma (5)  ·  Pancreatic Neoplasms (4)  ·  Carcinoma, Medullary (3)  ·  Bile Duct Neoplasms (2)  ·  Carcinoid Tumor (2)  ·  Carcinoma, Hepatocellular (2)

Broader conditions

Adenocarcinoma (33)  ·  Carcinoma (33)  ·  Digestive System Diseases (33)  ·  Digestive System Neoplasms (33)  ·  Endocrine Gland Neoplasms (33)  ·  Endocrine System Diseases (33)  ·  Neoplasms by Histologic Type (33)  ·  Neoplasms by Site (33)  ·  Neoplasms, Germ Cell and Embryonal (33)  ·  Neoplasms, Glandular and Epithelial (33)  ·  Neuroectodermal Tumors (33)  ·  Pancreatic Diseases (33)  ·  Carcinoma, Neuroendocrine (31)  ·  Pancreatic Neoplasms (29)  ·  Neoplasms (27)

Interventions

Capecitabine (5)  ·  Temozolomide (4)  ·  Bevacizumab (3)  ·  Fluorouracil (3)  ·  Leucovorin (3)  ·  Octreotide (3)  ·  Biological Therapy (2)  ·  Bortezomib (2)  ·  Cisplatin (2)  ·  Everolimus (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1)  ·  4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1)  ·  CTLA-4 Antigen (1)  ·  Carboplatin (1)

Sponsors

National Cancer Institute (NCI) (8)  ·  ECOG-ACRIN Cancer Research Group (3)  ·  Eastern Cooperative Oncology Group (2)  ·  Academic and Community Cancer Research United (1)  ·  Burzynski Research Institute (1)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  Columbia University (1)  ·  Delcath Systems Inc. (1)  ·  Emory University (1)  ·  Federation Francophone de Cancerologie Digestive (1)  ·  Grupo Espanol de Tumores Neuroendocrinos (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Ohio State University Comprehensive Cancer Center (1)

Countries

United States (27)  ·  Canada (1)  ·  France (1)  ·  Guam (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Mary Mulcahy, MD (2)  ·  Timothy Hobday (2)  ·  Arkadiusz Dudek, MD (1)  ·  Daniel Halperin (1)  ·  Ebrahim Delpassand, M.D. (1)  ·  Emily Bergsland (1)  ·  Emily K. Bergsland, MD (1)  ·  Guillaume Cadiot (1)  ·  Henry Pitot (1)  ·  James Yao (1)  ·  Jennifer Eads (1)  ·  Kyle Holen, MD (1)  ·  Lakshmi Rajdev (1)  ·  Leonard B. Saltz, MD (1)

Results publications

PMID 21831734, PMID 25318437, PMID 25488966, PMID 25956795, PMID 29853660, PMID 31969335, PMID 33362722, PMID 33835977, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36260828, PMID 37702588, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 39863139, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42225102, PMID 42499790

NIH funding

N01CM62205 (3), U10CA180820 (3), N01CM00039 (2), P30CA016672 (2), U10CA021115 (2), N01CM00032 (1), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62202 (1), N01CM62203 (1), N01CM62204 (1)